| Autor: |
Russo GI; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., Larganà G; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., Sebastianelli A; Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, 50100 Florence, Italy., Cocci A; Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, 50100 Florence, Italy., Mauro MD; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., Rapallo I; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., Morgia G; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., Morgia MM; Urology Section, Department of Surgery, University of Catania, 95100 Catania, Italy., La Vignera S; Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, Italy., Condorelli R; Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, Italy., Calogero AE; Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, Italy., Olivotto I; Cardiomyopathy Unit, Careggi University Hospital, 50100 Florence, Italy., Morselli S; Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, 50100 Florence, Italy., Serni S; Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, 50100 Florence, Italy., Gacci M; Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, 50100 Florence, Italy. |
| Abstrakt: |
Previous data have shown that patients with metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) could be refractory to the medical treatment. In this context, the evidence suggests a role for statin use in LUTS/BPE patients. The present systematic review aimed to evaluate the impact of statins on the treatment of men with LUTS/BPE. This review has been registered on PROSPERO (CRD42019120729). A systematic review of English-language literature was performed up to January 2020 in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA statement) criteria. Retrieved studies had to include adults with LUTS connected to BPE treated with statins drugs for metabolic syndrome. After removing duplicates, a total of 381 studies were identified by the literature search and independently screened. Of these articles, 10 fit the inclusion criteria and were further assessed for eligibility. Data from our systematic review suggest that a long-term therapy with statins, at least 6 months, is required to achieve significant impacts on prostate tissue and LUTS. Moreover, besides statins' direct activity, the risk reduction of LUTS might be connected to the improvement of hypercholesterolemia and MetS. The role of statins for the treatment of LUTS/BPE may be beneficial; however, evidence from robust studies is not enough, and more clinical trial are required. |
